Citalopram & Omeprazole Interaction

Omeprazole (Prilosec) inhibits the CYP2C19-mediated metabolism of citalopram (Celexa), increasing citalopram plasma concentrations by approximately 50-80% and potentially amplifying its dose-dependent QT-prolonging effect ^[1]. The FDA has established a maximum citalopram dose of 20 mg daily in patients taking CYP2C19 inhibitors, including omeprazole, due to the dose-dependent risk of QT prolongation and potentially fatal torsades de pointes ventricular arrhythmia ^[1]. This interaction is clinically significant because both medications are among the most commonly prescribed drugs — citalopram for depression and anxiety disorders, and omeprazole for gastroesophageal reflux disease and peptic ulcer disease ^[2].

QT prolongation is a cardiac conduction abnormality visible on ECG that predisposes patients to a specific type of ventricular tachycardia called torsades de pointes, which can degenerate into ventricular fibrillation and sudden cardiac death ^[3]. The risk increases with higher citalopram levels, electrolyte imbalances (hypokalemia, hypomagnesemia), female sex, pre-existing cardiac disease, and concurrent use of other QT-prolonging medications ^[1].

Citalopram is metabolized in the liver primarily by CYP2C19 and CYP3A4, with CYP2C19 being the more important pathway ^[1]. Omeprazole is both a substrate and a moderate inhibitor of CYP2C19, reducing the clearance of citalopram and increasing its steady-state plasma concentrations by approximately 50-80% ^[2]. At elevated concentrations, citalopram blocks the human ether-a-go-go-related gene (hERG) potassium channel in cardiac myocytes, which is responsible for the delayed rectifier potassium current (IKr) ^[1]. Blockade of IKr prolongs cardiac repolarization, manifesting as QT interval prolongation on the ECG ^[3]. The hERG channel blocking effect is concentration-dependent, meaning that the higher citalopram levels produced by CYP2C19 inhibition translate directly into greater QT prolongation ^[1].

Genetic polymorphisms in CYP2C19 further modify risk. Approximately 15-20% of individuals of European ancestry and up to 50% of East Asian populations are CYP2C19 poor metabolizers, who have intrinsically reduced citalopram clearance ^[2]. In these individuals, omeprazole co-administration produces even greater citalopram accumulation ^[1].

The FDA issued a Drug Safety Communication in 2011 warning that citalopram causes dose-dependent QT prolongation and should not exceed 40 mg daily in any patient, with a further reduction to 20 mg daily maximum in patients taking CYP2C19 inhibitors, patients over 60 years of age, and those with hepatic impairment ^[1]. A large observational study using FDA adverse event data linked citalopram to a higher rate of QT prolongation reports compared to other SSRIs ^[3]. While torsades de pointes remains rare in absolute terms, the consequences are catastrophic — sudden cardiac arrest with a survival rate dependent on immediate defibrillation ^[3]. Risk factors that compound the interaction include: hypokalemia (common in patients on diuretics), hypomagnesemia, bradycardia, female sex (women have longer baseline QT intervals), congenital long QT syndrome, heart failure, and concurrent use of other QT-prolonging drugs (antiarrhythmics, fluoroquinolone antibiotics, antipsychotics) ^[1].

Do not exceed citalopram 20 mg daily in patients taking omeprazole ^[1]. If a patient on citalopram >20 mg requires acid suppression, consider switching the PPI to one that does not inhibit CYP2C19: pantoprazole has the least CYP2C19 inhibition among PPIs and is preferred ^[2]. Alternatively, famotidine (an H2-receptor antagonist) does not inhibit CYP2C19 and provides adequate acid suppression for many patients ^[3]. If a patient on omeprazole requires an antidepressant, consider sertraline or escitalopram (at appropriate doses), which have lower QT prolongation risk ^[1]. Ensure electrolytes are normal — correct hypokalemia and hypomagnesemia, which independently prolong QT ^[3]. Avoid combining with other QT-prolonging medications when possible ^[1]. If the patient is on both medications at appropriate doses, obtain a baseline ECG and reassess if additional QT-prolonging risk factors develop ^[3].

Obtain a baseline ECG before starting the combination, particularly in patients with cardiac disease, electrolyte abnormalities, or other QT risk factors ^[1]. Repeat ECG if the dose of either medication is increased, if the patient develops cardiac symptoms (palpitations, syncope, near-syncope), or if additional QT-prolonging medications are added ^[3]. Check serum potassium and magnesium at baseline and periodically, especially in patients on diuretics ^[1]. A corrected QT interval (QTc) exceeding 500 milliseconds or an increase of >60 ms from baseline warrants immediate drug discontinuation and cardiology consultation ^[3]. Monitor for symptoms suggesting cardiac arrhythmia: palpitations, dizziness, lightheadedness, fainting, or seizures ^[1]. Drug concentrations of citalopram are not routinely measured in clinical practice, but if available, levels >100 ng/mL suggest significant CYP2C19 inhibition and increased risk ^[2].

Among PPIs, pantoprazole (Protonix) has the weakest CYP2C19 inhibitory effect and is preferred if PPI therapy is necessary in patients on citalopram ^[2]. Lansoprazole has moderate CYP2C19 effects — less than omeprazole but more than pantoprazole ^[2]. H2-receptor antagonists (famotidine, ranitidine alternatives) provide acid suppression without CYP2C19 inhibition ^[3]. Among antidepressants, sertraline (Zoloft) has minimal QT-prolonging effect and is less dependent on CYP2C19 for metabolism ^[1]. Escitalopram (Lexapro, the S-enantiomer of citalopram) also carries QT risk at high doses but has a lower maximum dose (20 mg) and may have a more favorable risk profile at appropriate doses ^[1]. Bupropion (Wellbutrin), mirtazapine (Remeron), and duloxetine (Cymbalta) are antidepressants with minimal QT prolongation risk ^[3]. Cognitive behavioral therapy should be considered as a non-pharmacologic intervention for depression and anxiety, particularly in patients with cardiac risk factors ^[1].